What's in Shanghai Huilun Pharmaceutical Co., Ltd.'s pipeline?

Shanghai Huilun Pharmaceutical Co., Ltd. has 2 drugs in our index: 0 marketed, 0 filed, 2 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Shanghai Huilun Pharmaceutical Co., Ltd.'s portfolio?

Top competitors by shared drug class: Sanofi, CHU de Quebec-Universite Laval, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Eli Lilly and Company, Haffkine Bio-Pharmaceutical Corporation Ltd..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/shanghai-huilun-pharmaceutical-co-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-18 · How we verify

Shanghai Huilun Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Shanghai Huilun Pharmaceutical Co., Ltd. pipeline: 0 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
H077 sustained-release tablet	H077 sustained-release tablet	phase 3	norepinephrine reuptake inhibitor	norepinephrine transporter	Depression
Silodosin capsules Control Group	Silodosin capsules Control Group	phase 3	Alpha-1 adrenergic receptor antagonist	Alpha-1 adrenergic receptor	Urology

Therapeutic area mix

Depression · 1
Urology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Sanofi · 2 shared drug classes
CHU de Quebec-Universite Laval · 1 shared drug class
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · 1 shared drug class
Eli Lilly and Company · 1 shared drug class
Haffkine Bio-Pharmaceutical Corporation Ltd. · 1 shared drug class
Hospital Authority, Hong Kong · 1 shared drug class
Japan Heart Foundation · 1 shared drug class
Kwang-Ha Yoo · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Shanghai Huilun Pharmaceutical Co., Ltd.:

Cite this brief

Drug Landscape (2026). Shanghai Huilun Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/shanghai-huilun-pharmaceutical-co-ltd. Accessed 2026-05-18.